Published in BMC Pulm Med on October 08, 2007
Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study. Lancet Respir Med (2015) 1.65
Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med (2010) 1.50
Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chron Obstruct Pulmon Dis (2012) 1.50
Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir Res (2011) 1.20
The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema. Am J Respir Crit Care Med (2010) 1.16
Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol (2010) 1.04
Gene promoter methylation is associated with lung function in the elderly: the Normative Aging Study. Epigenetics (2012) 0.95
Chronic obstructive pulmonary disease and the metabolic syndrome: Consequences of a dual threat. Indian J Endocrinol Metab (2014) 0.92
The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases. Chest (2012) 0.89
Ageing and smoking contribute to plasma surfactant proteins and protease imbalance with correlations to airway obstruction. BMC Pulm Med (2011) 0.89
Surfactant protein D, a clinical biomarker for chronic obstructive pulmonary disease with excellent discriminant values. Exp Ther Med (2016) 0.81
Factors influencing the measurement of plasma/serum surfactant protein D levels by ELISA. PLoS One (2014) 0.80
Biomarkers in chronic obstructive pulmonary disease: confusing or useful? Int J Chron Obstruct Pulmon Dis (2014) 0.80
Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease. Respir Res (2014) 0.79
Repression of CC16 by cigarette smoke (CS) exposure. PLoS One (2015) 0.79
Value of serum and induced sputum surfactant protein-D in chronic obstructive pulmonary disease. Multidiscip Respir Med (2013) 0.79
Mass casualties and health care following the release of toxic chemicals or radioactive material--contribution of modern biotechnology. Int J Environ Res Public Health (2011) 0.77
Bone mineral density among elderly patients with chronic obstructive pulmonary disease patients in India. Niger Med J (2013) 0.77
Role of serum and induced sputum surfactant protein D in predicting the response to treatment in chronic obstructive pulmonary disease. Exp Ther Med (2014) 0.76
The role of serum surfactant protein D as a biomarker of exacerbation of chronic obstructive pulmonary disease. Qatar Med J (2016) 0.76
Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs. Biomark Insights (2016) 0.76
Functional capacity, health status, and inflammatory biomarker profile in a cohort of patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev (2015) 0.76
Serum surfactant protein D (SP-D) is a prognostic marker of poor outcome in patients with A/H1N1 virus infection. Lung (2014) 0.76
The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.75
Serum Levels of Surfactant Proteins in Patients with Combined Pulmonary Fibrosis and Emphysema (CPFE). PLoS One (2016) 0.75
Club Cell-16 and RelB as Novel Determinants of Arterial Stiffness in Exacerbating COPD Patients. PLoS One (2016) 0.75
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet (1997) 25.40
C-reactive protein: a critical update. J Clin Invest (2003) 11.77
Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax (2003) 2.47
C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax (2006) 2.38
What does minor elevation of C-reactive protein signify? Am J Med (2006) 2.14
Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J Immunol (2000) 2.12
Prognostic value of surfactant proteins A and D in patients with acute lung injury. Crit Care Med (2003) 1.96
Surfactant protein-D regulates surfactant phospholipid homeostasis in vivo. J Biol Chem (1998) 1.77
COPD: current therapeutic interventions and future approaches. Eur Respir J (2005) 1.61
Surfactant protein A and surfactant protein D in health and disease. Am J Physiol (1998) 1.56
Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med (1995) 1.42
Surfactant protein-D, a mediator of innate lung immunity, alters the products of nitric oxide metabolism. Am J Respir Cell Mol Biol (2003) 1.21
Serum surfactant protein D is elevated in allergic patients. Clin Exp Allergy (2004) 1.20
Serum levels of CC16, SP-A and SP-B reflect tobacco-smoke exposure in asymptomatic subjects. Eur Respir J (2002) 1.18
Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur Respir J (2000) 1.13
Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res (2006) 1.04
Serum KL-6 and surfactant proteins A and D in pediatric interstitial lung disease. Chest (2005) 0.98
Serum surfactant protein D is increased in acute and chronic inflammation in mice. Cytokine (2005) 0.97
Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest (2007) 0.90
Determinants of serum levels of surfactant proteins A and B and Clara cell protein CC16. Biomarkers (2004) 0.89
Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis. Eur Respir J (2003) 0.85
The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.85
Acute exacerbation of chronic obstructive pulmonary disease: influence of social factors in determining length of hospital stay and readmission rates. Can Respir J (2008) 1.28
The influence of gender on the effects of aspirin in preventing myocardial infarction. BMC Med (2007) 0.92
Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest (2007) 0.90
The relationship between stage 1 and 2 non-small cell lung cancer and lung function in men and women. BMC Pulm Med (2006) 0.77
Developments in drugs for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Immunol (2008) 0.75